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Abstract
The N-formyl peptide receptors (FPRs) have been identified within neuronal tissues and
may serve as yet undetermined functions within the nervous system. The FPRs have been
implicated in the progression and invasiveness of neuroblastoma and other cancers. In this
study the effects of the synthetic FPR agonist FPRa14, FPR antagonists and FPR knock-
down using siRNA on mouse neuroblastoma neuro2a (N2a) cell differentiation plus toxicity
were examined. The FPRa14 (1–10μM) was found to induce a significant dose-dependent
differentiation response in mouse neuroblastoma N2a cells. Interestingly, three distinct dif-
ferentiated morphologies were observed, with two non-archetypal forms observed at the
higher FPRa14 concentrations. These three forms were also observed in the human neuro-
blastoma cell-lines IMR-32 and SH-SY5Y when exposed to 100μM FPRa14. In N2a cells
combined knockdown of FPR1 and FPR2 using siRNA inhibited the differentiation response
to FPRa14, suggesting involvement of both receptor subtypes. Pre-incubating N2a cultures
with the FPR1 antagonists Boc-MLF and cyclosporin H significantly reduced FPRa14-
induced differentiation to near baseline levels. Meanwhile, the FPR2 antagonist WRW4 had
no significant effect on FPRa14-induced N2a differentiation. These results suggest that the
N2a differentiation response observed has an FPR1-dependent component. Toxicity of
FPRa14 was only observed at higher concentrations. All three antagonists used blocked
FPRa14-induced toxicity, whilst only siRNA knockdown of FPR2 reduced toxicity. This sug-
gests that the toxicity and differentiation involve different mechanisms. The demonstration
of neuronal differentiation mediated via FPRs in this study represents a significant finding
and suggests a role for FPRs in the CNS. This finding could potentially lead to novel thera-
pies for a range of neurological conditions including neuroblastoma, Alzheimer’s disease,
Parkinson’s disease and neuropathic pain. Furthermore, this could represent a potential
avenue for neuronal regeneration therapies.
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Introduction
The N-formyl peptide receptors (FPRs) are a family of G-protein-coupled receptors that were
initially identified in phagocytic leukocytes, however subsequent reports have demonstrated
FPRs to be expressed in multiple non-myeloid cell types and tissues throughout the body
including the central nervous system (CNS) [1,2], and by virtue many novel physiological and
pathophysiological roles for this receptor family have been described [3]. In humans, three sep-
arate FPR isoforms have been defined: FPR1, FPR2/ALX (formerly FPRL1) & FPR3 (formerly
FPRL2), each encoded by a separate gene (FPR1, FPR2 & FPR3 respectively) [4]. FPR1 is the
most commonly expressed FPR isoform in humans with high concentrations found in neuro-
nal tissues, including the spinal cord, cerebellar system, hippocampus, as well as neurons of
the sensory system, sympathetic and parasympathetic systems [2]. FPR2/ALX distribution
closely mimics that of FPR1 and it is posited that these isoforms share overlapping functions in
the immune system [5]. The mouse FPR (mFPR) family includes at least eight mFPR isoforms
[6,7]. He et al. [8] studied the mouse homologs of FPR1, FPR2/ALX and FPR3 and demon-
strated promiscuous binding properties and only slight differences in the responses to FPR
ligands relative to the human equivalents. The putative functions of the additional mFPRs pre-
dominantly lie with olfaction, which mice rely heavily upon for communication and environ-
mental feedback [9].
Recent studies have highlighted the involvement of FPRs in the progression of several neu-
rological cancers. Neuroblastoma primary tumors and cell lines have been found to express
FPR1; increased expression of which is correlated with high-risk disease and low survival rates
[10]. Knockdown of FPR1 with shRNA delayed neuroblastoma development, while ectopic
overexpression of FPR1 elicited augmented tumorigenesis in nude mice [10]. FPRs have been
demonstrated to be expressed by human glioblastoma cell lines, in which it has been suggested
that FPR activation exacerbates tumor malignancy through the production of angiogenic fac-
tors and the activation of epidermal growth factor [11]. Highly malignant human glioblasto-
mas have been reported to selectively overexpress FPR1, with activation promoting cancer
progression and metastasis [12]. Both formylated peptides and Annexin A1 released from
necrotic glioblastoma cells have been demonstrated to promote tumor growth via activation of
FPR1 [13]. Activation of FPR1 in human astrocytoma cell lines promotes motility, growth and
angiogenesis. Targeting FPR1 with a specific antagonist was found to reduce astrocytoma cell
motility and activation, thus prolonging the survival of tumour-bearing mice [14]. These stud-
ies demonstrate that the stimulation of FPR in neurological cancer cells leads to FPR upregula-
tion in order to increase cell proliferation and tumor growth in an autocrine or paracrine
manner. However, discrete changes in FPR modulation can lead to a range of biological
responses depending on the cellular context, and as such FPR upregulation has been shown to
produce stimulatory and inhibitory effects upon tumor progression depending on the cancer
histotype [15].
FPRs respond to a vast number of structurally diverse ligands including endogenous pep-
tides, bacterial derived peptides, synthetic library-derived peptides plus small non-peptide
molecules and lipids. This unusual diversity of ligands has led to the classification of FPRs as
pattern recognition receptors [16]. Interestingly, a number of endogenous FPR agonists have
been linked with the pathogenesis of several neurodegenerative diseases. For example, FPR2/
ALX has demonstrated to be a functional receptor for prion protein fragment PrP106-126, as
well as the amyloidogenic peptides serum amyloid A and amyloid-β; which play important
roles in the neurodegenerative activity of Alzheimer’s disease (AD) and prion diseases
[17,18,19]. FPR activation is understood to mediate the pro-inflammatory activity of these
amyloidogenic agonists via activation of microglia, the infiltration from the blood supply of
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mononuclear phagocytes exhibiting amplified adhesion, leukocyte recruitment and the pro-
duction of pro-inflammatory cytokines, leading to a chronic neuroinflammatory response
[20]. Conversely, FPR2/ALX has shown to mediate anti-inflammatory processes if activated by
Annexin A1 leading to amyloid-β degradation [21]. It has also been suggested that FPRs medi-
ate the uptake and fibril formation of amyloid-β in AD; transient FPR2/ALX activation in
macrophages by amyloid-β stimulates rapid internalisation and degradation of the protein,
however chronic stimulation leads to a build-up of amyloid-β-FPR complexes leading to the
formation of fibrillar aggregates [22].
Two recent studies have demonstrated that FPR1 and FPR2 activation within mouse neural
stem cells elicits proliferation and differentiation [23] via reactive oxygen species (ROS) acti-
vated pathways [24]. This is of particular interest, because if this differentiation response is
replicable in other neuronal cells, it would provide evidence of a potential physiological role
for FPRs within the nervous setting, and furthermore could highlight the FPR as a novel thera-
peutic target for neuronal regeneration. In the present study, the synthetic nonselective FPR
agonist FPRa14 [25] was investigated for its ability to produce neuronal differentiation within
cultured mouse neuroblastoma Neuro-2a (N2a) cells.
Materials and methods
Materials
Mouse and Human Neuroblastoma cells (N2a (ECACC 89121404), IMR-32 (ECACC
86041809), SH-SY5Y (ECACC 94030304)) were obtained from European Collection of
Authenticated Cell Cultures (UK). Eagle’s Minimum Essential Medium high glucose (EMEM),
Dulbecco’s Modified Eagle’s Medium high glucose (DMEM), all additional media components
and cyclosporin H were purchased from Sigma Aldrich (UK). FPRa14, Boc-MLF and WRW4
were obtained from Tocris Bioscience (UK). SilencerTM select siRNA duplexes for mouse Fpr1
(siRNA ID s66215), mouse Fpr2 (siRNA ID 66212) plus negative control no.1 siRNA and
Lipofectamine RNAiMAX were purchased from ThermoFisher Scientific (UK). All other
chemicals used were of reagent grade.
Cell culture conditions
N2a cells were cultured in DMEM containing 2mM glutamine, 100μg/ml penicillin, 100μg/ml
streptomycin, and 10% (v/v) heat inactivated fetal bovine serum (complete DMEM). IMR-32
and SH-SY5Y cells were cultured in EMEM containing 2mM glutamine, 100μg/ml penicillin,
100μg/ml streptomycin, and 10% (v/v) heat inactivated fetal bovine serum (complete EMEM).
For siRNA transfections N2a cells were cultured in serum-free antibiotic-free DMEM. Cells
were incubated under standard conditions of: 37˚C, 5% CO2 in a humidified atmosphere. Cul-
tures were passaged at regular intervals, once at 70–80% confluence.
Cell differentiation assay
N2a, IMR32 and SHSHY-5Y cells were seeded at a density of 5000 cells/well into a 24-well cul-
ture plate in complete culture medium (400μL/well) and incubated under standard culture
conditions for 24h. Complete culture medium was aspirated and wells were washed with PBS
before treatment with serum-free culture medium (SFM) containing FPRa14 (0–10μM). Cells
treated with SFM alone served as a negative control. The cells were then incubated under stan-
dard culture conditions for 48h in order to observe any morphological changes. For cell differ-
entiation assays with FPR antagonists, cells were pre- incubated with Boc-MLF (0–40μM),
cyclosporin H (0–40μM) or WRW4 (0–40μM) for 30min before addition of FPRa14 (8μM).
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Quantification of cell differentiation
Four random fields were examined in each well using an EVOS FL Auto 2 cell imaging system
with 20x objective. Images were collected at specified timepoints up to 48h after FPRa14
administration. All quantitative morphological analyses were performed using ImageJ soft-
ware (NIH). Differentiated cells were defined as any cell bearing one or more axon-like pro-
cesses more than or equal to the length of the cell body radius, or that exhibited abnormal
morphology traits. Morphological changes were quantitatively assessed via morphometric
measurements of cell perimeter and area using tracing tool measurements on ImageJ [26,27].
Cells were also subjectively categorised by morphology type. Exclusionary criteria during
image analysis were: any cell touching the image border or substantial cell clumps.
siRNA transfections
Two siRNA duplexes targeting Fpr1, Fpr2 plus a third negative control knockdown duplex
were used. Transfections were carried out using Lipofectamine RNAiMAX in antibiotic-free
serum-free DMEM. Lipofectamine RNAiMAX and siRNA duplexes (10μM stock in nuclease-
free water) were diluted separately in antibiotic-free serum-free DMEM in a v/v ratio of 1.5:25
and 1:50 respectively. Diluted siRNA was then added to diluted Lipofectamine in a 1:1 ratio
and incubated at room temperature for 5min. siRNA-lipid complexes then added to sub-con-
fluent N2a cells; 10μL per well for 96-well plate assays giving a final siRNA concentration of
1pM and 0.3μL Lipofectamine per well, and 50μL per well was used for 24-well plate assays giv-
ing a final siRNA concentration of 5pM and 1.5μL Lipofectamine per well. For simultaneous
Fpr1 and Fpr2 knockdown, the Fpr1 and Fpr2 siRNA duplexes were added to 0.6μL Lipofecta-
mine (96-well) at a final well concentration of 1pM, and 5pM with 3μL Lipofectamine
(24-Well). Transfected cells were then incubated at 37˚C, 5% CO2 for 48h before treatment
with FPRa14 agonist [28].
MTT cell viability assay
N2a cells were seeded at a density of 20,000 cells/well into a flat-bottom 96-well culture plate in
complete DMEM (100μL/well) and incubated under standard culture conditions for 24h. N2a
cells were then exposed to SFM containing FPRa14 (0-10mM) and incubated for a further 24h.
The MTT assay was then conducted according to Mosmann [29]. Absorbance was measured
at 550nm (test) and 690nm (background). Results were expressed as percentage control MTT
reduction. For antagonist experiments, cells were pretreated with SFM containing Boc- MLF,
cyclosporin H or WRW4 (0–40 μM) and incubated for 30 minutes prior to agonist exposure.
Methods of statistical analysis
All the experimental data are expressed as mean ± standard error of the mean (SEM). Statisti-
cal differences between groups were calculated by unpaired Student’s t-tests for individual
comparisons, or ANOVA with Dunnett’s post-hoc test for multiple comparisons. Analysis was
performed on data from at least three independent experiments. P<0.05 was considered to be
statistically significant between groups. Statistical analysis was performed using SPSS version
24.
Results
FPRa14-induced cell differentiation
FPRa14 stimulated a demonstrable cellular differentiation response in neuroblastoma cell lines
as shown in the typical phase-contrast microscope images displayed in Fig 1 for N2a (Fig 1A
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and 1B), IMR-32 (Fig 1C and 1D) and SH-SY5Y (Fig 1E and 1F). The differentiation induced
in N2a cells by FPRa14 was seen at 10μM concentrations, however in IMR-32 and SH-SY5Y a
concentration of 100μM was required to produce similar effects. As a result characterization of
the differentiation responses was performed on N2a cells to reduce potential for non-specific
effects of both agonists and antagonists.
After 24h incubation, the mean proportion of differentiated cells in control cultures was
2.4% (Fig 2A). FPRa14 caused a significant increase in % cell differentiation relative to SFM
treated controls at concentrations of 2μM (12.4%), 4μM (18.5%), 6μM (25.7%), 8μM (59.6%)
and 10μM (87.0%). After 48h, the mean proportion of differentiated cells in control cultures
was 20.4%. FPRa14 elicited a significant increase in % cell differentiation versus controls at
concentrations of 4μM (32.0%), 6μM (64.9%), 8μM (89.1%) and 10μM (93.3%).
Alteration of cell perimeter and cell area were selected as secondary measures of cell differ-
entiation (Fig 2B and 2C). Differentiated N2a cells generally showed cell perimeters and areas
greater than their undifferentiated counterparts. After 24h, it was found that there was a signif-
icant difference in mean cell perimeter between SFM control cultures and cultures treated
with FPRa14 at concentrations of 8μM and 10μM. After 48h, there was a significant difference
in mean cell perimeter between controls and cultures treated with FPRa14 at concentrations of
6μM, 8μM and 10μM. Similarly cell areas were found to significantly increase in cultures
treated with 6, 8 and 10μM FPRa14 relative to untreated controls after both 24 and 48h incuba-
tions. Cell numbers showed a decrease in the presence of FPRa14 which reached significance
at 10μM when incubated for 24h (Fig 2D). Following 48h incubation with FPRa14 decreases
in cell number were observed at concentrations of 8μM and above.
N2a cells which differentiated in response to FPRa14 exhibited three distinct cell body traits
(Fig 3A) all of which were clearly distinct from undifferentiated cells. Some cells exhibited
archetypal neurite formation and outgrowth (Type A), others formed into large ‘amoeboid’
structures (Type B), while others exhibited diminished cell bodies, but multiple large pro-
cesses, forming a ‘star-like’ structure (Type C). Trypan blue dye exclusion was used to deter-
mine % viability of each of the forms observed. Following treatment with FPRa14 (2–10μM)
for 48h the viabilities were: Undifferentiated = 59.5%, Type A = 64.0%, Type B = 85.5% and
Type C = 67.2%. There were also some notable trends in the distribution of these morphology
types (Fig 3B): in control cultures, the only recorded differentiated cell morphology was Type-
A. The Type-B cell bodies were only recorded in cultures treated with FPRa14 at concentra-
tions� 4μM, increasing in frequency in a dose dependent fashion. Type-C morphologies only
existed in cultures treated with the FPRa14 at concentrations� 6μM, once again becoming
more prominent as the FPRa14 concentration increased. The perimeters and areas of each of
the 4 cell morphologies were determined using ImageJ. All three differentiated morphologies
showed significant increases in cell perimeter relative to undifferentiated control (Fig 3C) with
the Type C (star-like) showing the greatest increase, whereas only the Type B form (amoeboid)
showed a significantly increased cell area (Fig 3D).
Time course of FPRa14-induced cell differentiation
In order to more closely examine the morphological changes of N2a cells during FPRa14-dri-
ven cell differentiation, additional cell differentiation assays were conducted in which images
were collected at 1, 2, 4, 6, 8, 24 and 48h after treatment with FPRa14 (10μM). N2a cells were
found to differentiate rapidly in response to FPRa14 (Fig 4A). The proportion of differentiated
cells at the point of agonist administration was 3.5%. After 1h incubation, % cell differentiation
rose to 36.0% and after 2h, this value had climbed to 72.7%. Thereafter % cell differentiation
stabilised (4h = 82.9%, 6h = 85.3%, 8h = 86.5%), with 24 and 48h % cell differentiation values
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of 86.9% and 94.0% respectively. Time-lapse data also revealed some noteworthy information
on the distribution of differentiated cell phenotypes. 1h after FPRa14 administration, mor-
phology types A, B and C (Fig 3A) were all observed. Type A differentiated cells underwent a
transient increase in frequency, peaking at 4h where they accounted for 15.6% of the total cell
population, before then diminishing in frequency, making up 2.1% of the total cell population
Fig 1. Typical phase contrast photomicrographs (200x) exhibiting (A) untreated N2a, (B) N2a treated with 10μM
FPRa14, (C) untreated IMR-32, (D) IMR-32 treated with 100μM FPRa14 (E) untreated SH-SY5Y and (F) SH-SY5Y
treated with 100μM FPRa14. Images were taken after 48h incubation (scale bars represent 100μm).
https://doi.org/10.1371/journal.pone.0217815.g001
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at time-point 24h. Type A differentiated cells were once again found to increase in frequency
between 24 and 48h time-points. Type B differentiated cells gradually increased in frequency
with incubation time. This differentiated form accounted for 18.6% of the total cell population
after 1h, and this value increased with each time-point, constituting 65.0% of the total cell pop-
ulation at time-point 48h. Type C differentiated cell frequency saw steady increases up to
time-point 4h, where they accounted for 30.9% of the total cell population. Type C frequency
Fig 2. (A) The effect of FPRa14 (0–10μM) on (A) the % differentiated N2a cells, (B) mean N2a cell perimeter, (C) mean N2a cell area and (D) mean cell
count. Serum-free medium only was used as a control. Values represent mean ± SEM, taken following 24h and 48h incubation with FPRa14. Statistical
analysis was performed via one-way ANOVA with Dunnett’s post hoc test. �Represents statistical significance (P<0.01) relative to appropriate incubation
control. Mean total cell counts are expressed as a percentage of control.
https://doi.org/10.1371/journal.pone.0217815.g002
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then remained relatively stable until 24h where they comprised 30.2% of the total cell
population.
Time-lapse cell differentiation assays were also performed in order to determine the effect
of short-term exposure to FPRa14 on the N2a cell differentiation response. N2a cells were
again treated with FPRa14 (10μM), however on this occasion cultures were incubated for 1h
before the FPRa14-containing media was aspirated, wells washed with PBS, and fresh SFM
added (Fig 4B). This additional wash step reduced the proportion of differentiated cells in
FPRa14-removed versus FPRa14-containing cultures during early stage differentiation. At
time-point 8h FPRa14-removed N2a cultures started to achieve % cell differentiation values
close to that observed in their agonist-containing counterparts. The addition of this wash step
after 1h agonist exposure had little effect on the frequency and distribution of differentiated
morphology phenotypes.
Fig 3. (A) Key highlighting examples of the three classes of differentiated cell morphology observed following incubation with FPRa14 (2–
10μM). Images were taken 48h incubation with FPRa14. (B) The effect of FPRa14 (0–10μM) on differentiated cell morphology distribution
following 48h incubation with FPRa14. (C) Mean perimeter values for each N2a morphology type observed in cultures treated with FPRa14 (0–
10μM). (D) Mean area values for each N2a morphology type observed in cultures treated with FPRa14 (0–10μM). Statistical analysis was
performed via one-way ANOVA with Dunnett’s post hoc test. �Represents statistical significance (P<0.01) relative to undifferentiated control
(UD).
https://doi.org/10.1371/journal.pone.0217815.g003
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Effect of siRNA targetting of Fpr1 and Fpr2 upon FPRa14-induced
differentiation
In order to determine whether FPR1 and FPR2 play a functional role in the observed N2a cell
responses to FPRa14, a series of siRNA knockdown experiments were conducted.
The effect of FPR inhibition using siRNA upon FPRa14 induced differentiation was
assessed using subconfluent N2a cells 48h post transfection with siRNA duplexes targeting
Fpr1, Fpr2, simultaneous targetting of Fpr1 and Fpr2 and a negative control duplex. Individual
treatment with siRNA against Fpr1 and Fpr2 produced no significant change in % cell differ-
entiation relative to negative siRNA controls when treated with FPRa14 at concentrations of
2.5–10μM (Fig 5A). However when combined Fpr1 and Fpr2 siRNAs were used, there was a
significant reduction in % cell differentiation relative to negative control siRNA treated N2a
cells at FPRa14 at concentrations of 2.5–10μM.
Distribution of cells across the three differentiated morphology types varied with the siRNA
treatments. Control siRNA treatment resulted in a similar distribution of Types A, B and C in
response to FPRa14 (Fig 5B) to that seen in wild-type FPRa14 treated N2a cells (Fig 3B). The
Fpr2 siRNA had no effect on cell morphology distribution in response to FPRa14 when used
in isolation. The Fpr1 siRNA resulted in a significant increase in the proportion of type B mor-
phologies and a significant decrease in type C morphologies (Fig 5B) whilst not impacting the
overall percentage differentiation (Fig 5A). Simultaneous treatment with Fpr1 and Fpr2 siR-
NAs resulted in significant decreases in the proportion of Type B and C morphologies (Fig
5B) and overall percentage differentiation (Fig 5A). This suggests that FPRa14 acts via FPR1
to induce Type C morphologies, whilst the Type B morphologies can be induced by FPRa14
acting via either FPR1 or FPR2.
Effect of FPR antagonists on FPRa14-induced differentiation
The effects of FPR antagonists on FPRa14 induced differentiation were assessed using N2a
cells pre-incubated in the presence of FPR1 antagonists Boc-MLF or cyclosporin H, or the
FPR2/ALX antagonist WRW4 prior to the administration of FPRa14. After 48h treatment
with FPRa14, the mean proportion of differentiated cells was 88.5% in the absence of antago-
nist (Fig 5C). Pre-incubating cells with Boc-MLF or cyclosporin H caused a significant reduc-
tion in the FPRa14 induced cell differentiation at concentrations of 5μM and above.
Cyclosporin H appeared more potent in inhibition of FPRa14-induced differentiation when
used at concentrations of 10μM or higher. Pre-incubation with WRW4 (up to 40μM) pro-
duced no significant change in % cell differentiation stimulated by FPRa14. Boc-MLF (40μM),
cyclosporin H (40μM) and WRW4 (40μM) in the absence of FPRa14 had no significant effect
on differentiation relative to serum-free medium controls (Fig 5D).
MTT cytotoxicity assay
FPRa14 stimulated a dose dependent toxicity as assessed using MTT assay in control siRNA
treated cells. This toxicity was unaffected by Fpr1 siRNA treatment, but was attenuated in the
presence of Fpr2 siRNA (Fig 6A). FPRa14 stimulated a significant dose-dependent inhibition
of MTT reduction (Fig 6B), in a similar maner to FPRa14 with control siRNA. In the presence
Fig 4. (A) The effect of FPRa14 (10μM) on the % of differentiated N2a cells and differentiated cell morphology
distribution at time points of 0-48h following agonist administration (n = 1580). (B) The effect of FPRa14 (10μM) on
the % of differentiated N2a cells and differentiated cell morphology distribution at time points of 0-48h when the
agonist-containing media was removed after 1h incubation in the presence of FPRa14 agonist (as indicated by dotted
line) and replaced with SFM (n = 1293).
https://doi.org/10.1371/journal.pone.0217815.g004
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of FPR1 (Fig 6B) and FPR2 (Fig 6C) antagonists there was a significant attenuation of this tox-
icity. The highest FPRa14 concentration used in cell differentiation assays (10μM) stimulated a
significant toxicity that was also reversed by FPR1 and 2 antagonists (Fig 6D).
Fig 5. (A) The effect of FPRa14 (0–10μM) on the percentage differentiation of N2a cells following control siRNA, Fpr1, Fpr2, and simultaneous Fpr1 &
Fpr2 siRNA treatment. (B) The effect of FPRa14 (10μM) on the proportion of the differentiated cell morphology types following Fpr1, Fpr2, and
simultaneous Fpr1 & Fpr2 siRNA treatment. N2a cells were also transfected with a negative control siRNA duplex as a control. Values represent mean
±SEM, following 24h incubation with FPRa14. Statistical analysis was performed via one-way ANOVA with Dunnett’s post hoc test. �Represents
statistical significance (P<0.01) relative to appropriate negative control siRNA (n = 1120). (C) The effect of FPRa14 (8μM) on the % of differentiated N2a
cells after 30min incubation with Boc-MLF (0–40μM), cyclosporin H (0–40μM) or WRW4 (0–40μM). Serum-free medium only (SFM) was used as a
negative control (n = 1121). (D) The effect of Boc-MLF only (40μM), cyclosporin H only (40μM), WRW4 only (40μM) and SFM on the % of
differentiated N2a cells (n = 355). Values are mean ±SEM, taken after 48h of incubation with FPRa14. Statistical analysis was performed via one-way
ANOVA with Dunnett’s post-hoc test. �Represents statistical significance (P<0.01) relative to serum-free medium control.
https://doi.org/10.1371/journal.pone.0217815.g005
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Discussion
The synthetic FPR agonist FPRa14 stimulated clear dose-dependent increases in N2a cell dif-
ferentiation. Similar differentiation effects were observed in IMR-32 and SH-SY5Y cells, but
required a ten-fold higher concentration of FPRa14 to induce these effects (Fig 1). The differ-
entiation responses were characterized by measurement of percentage differentiation, cell
perimeter measurements and cell area measurements (Fig 2). The use of serum free media as a
vehicle for FPRa14 promoted differentiation in control experiments in agreement with pub-
lished literature [30]. As such the actions of FPRa14 could be additive on an already induced
differentiation. The FPRa14-induced differentiation effect in N2a cells was inhibited when cul-
tures were pre-incubated with the FPR1 antagonists Boc-MLF and cyclosporin H [31], demon-
strated by decreases in percentage cell differentiation to approximately untreated control
values (Fig 5C), whilst pre-incubating N2a cultures with the FPR2/ALX antagonist WRW4
had no significant effect upon FPRa14-stimulated N2a cell differentiation. Pharmacologically
these results suggest that FPRa14 induces differentiation via an action on the FPR1 receptor
type. Treatment with siRNAs against Fpr1 and Fpr2 only reduced the overall differentiation
when used in combination, suggesting that the differentiation could be induced via either
FPR1 or FPR2, and it is possible that the effects with FPR1 antagonists could be due to non-
specific actions on FPR2 receptors which has been reported previously for the higher doses
used in our study [16]. FPRa14 induced a number of differentiated N2a phenotypes (‘neurite
outgrowth’ designated Type A, ‘amoeboid’ designated Type B and ‘star-like’ designated Type
C) (Fig 3A) in a concentration dependent manner. The cell perimeters were significantly
increased in all differentiated forms, but more so for Type C differentiation (Fig 3C), whereas
the cell areas were only significantly changed in Type B differentiation (Fig 3D). These
changes become more pronounced at increased FPRa14 concentrations, which accompany
changes in distribution between the differented cell types (Fig 3B).
Differentiation into Type B was inhibited by combination Fpr1 and Fpr2 siRNA treatment
in agreement with the overall effects on differentiation which had suggested either FPR1 or
FPR2 involvement. However the Type C form was reduced in the presence of Fpr1 siRNA sug-
gesting that differentiation into this form is FPR1 mediated. Multiple second messenger path-
ways have been implicated in the actions of FPR1 and FPR2 [24,32,33]. This suggests that
identifying signaling pathways involved in Type B and Type C formation may be complex due
to the involvement of multiple receptor types and potentially multiple signaling pathways. One
way of further characterizing this would be to combine immunohistochemical analysis of sig-
naling protein changes plus specific neuronal markers which may aid identification and cate-
gorization of the subtypes.
Time-lapse analysis (Fig 4) revealed interesting insights into N2a responses to FPRa14. An
immediate observation that can be made is the swift nature of FPRa14-driven differentiation,
with the proportion of differentiated cells reaching 82.9% after just 4h of agonist exposure (Fig
4A). Another noteworthy finding is the presence of A, B and C differentiated phenotypes in
N2a cultures at both time-points of 1h and 48h post FPRa14 administration. This could sug-
gest that each phenotype exists independently of one another, rather than a transitional differ-
entiation from neurite outgrowth leading to ‘amoeboid’ and ‘star-like’. Removal of the agonist
after 1h (Fig 4B), thus removing the agonist and any secreted modulators from the extracellu-
lar environment, caused a slight delay in cell differentiation. However the removal of the extra-
cellular stimulus had little effect on the eventual differentiated cell phenotype distribution
observed. FPRs have been widely shown to undergo homologous desensitisation upon contin-
uous stimulation by the same ligand, driven by changes in phosphorylation, internalisation
and down-regulation of expression [34,35]. The E. coli -derived formyl peptide fMLF has been
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Fig 6. (A) The effect of FPRa14 (0-10mM) on % control MTT reduction in N2a cells following control siRNA, Fpr1, Fpr2, and simultaneous Fpr1 & Fpr2
siRNA treatment. Values represent mean ±SEM, following 24h incubation with FPRa14. Statistical analysis was performed via one-way ANOVA with
Dunnett’s post-hoc test. �Represents statistical significance (P<0.01) relative to negative control siRNA plus FPRa14. (B) The effect of FPRa14 (0-10mM)
alone, FPRa14 (0-10mM) following 30min pre-incubation with Boc-MLF (40μM) or cyclosporin H (40μM) on N2a % control MTT reduction. (C) The
effect of FPRa14 (0-10mM) alone and FPRa14 (0-10mM) following 30min pre-incubation with WRW4 (40μM) on N2a % control MTT reduction. Values
are mean ±SEM from six repeats. Statistical analysis was performed via one-way ANOVA with Dunnett’s post-hoc test. �Represents statistical significance
(P<0.01) relative to positive FPRa14 control. (D) The effect of FPRa14 (10μM) alone or serum free media and FPRa14 (10μM) or serum free media
following 30min pre-incubation with Boc-MLF (40μM), cyclosporin H (40μM) or WRW4 (40μM) on N2a % control MTT reduction. Values are mean
±SEM from six repeats. Statistical analysis was performed via one-way ANOVA with Dunnett’s post hoc test. �Represents statistical significance (P<0.01)
relative to serum free media, # represents statistical significance (P<0.01) relative to FPRa14 (10μM).
https://doi.org/10.1371/journal.pone.0217815.g006
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shown to undergo internalisation within 30 seconds of binding FPR1 [36]. FPR signaling is
typically driven though G-protein interactions, however upon internalisation, it has been sug-
gested that the occupied FPR quickly couples with the cytoskeleton within the plasma mem-
brane [37]. In desensitised cells, FPRs are confined to domains with little access to G-proteins,
but are instead exposed to cytoskeletal proteins such as actin; thereby halting G-protein related
signaling and instead activating cytoskeletal transduction pathways [38]. Furthermore, when
associated with the cytoskeleton, FPR has been shown to enter a “super high affinity state”
characterised by an extremely low rate of dissociation of bound ligand [39]. This could explain
the formation of amyloid-β-FPR complexes leading to the formation of fibrillar aggregates
[22]. These high affinity states have also been demonstrated in other GPCR receptor types
such as lectin-induced association of nerve growth factor receptors with the cytoskeleton of
PC-12 cells leading to a five-fold decrease in receptor dissociation rates [40]. It is plausible that
the FPRa14 ligand is internalised upon receptor activation, where FPR-FPRa14 complexes can
bind to and activate certain cytoskeletal processes leading to cellular differentiation. Once
associated with the N2a cytoskeleton, the rate of dissociation of FPRa14 ligand from its recep-
tor may decrease, meaning that continuous stimulation is not necessary for cellular differentia-
tion to continue. Our experiments with removal of the agonist containing media after 1h are
unlikely to modify this type of action.
Cytotoxic effects of FPRa14 on N2a cells were characterised via MTT assay (Fig 6). The
dose-dependent toxicity was inhibited by FPR1 and FPR2 antagonists, however the effect was
only reduced by siRNA when Fpr2 was targeted. This suggests that the toxicity response is via
the FPR2 receptor and that the effects observed were due to a loss of specificity of the FPR1
antagonists at the doses used. It has been reported that Boc-MLF and cyclosporin H are spe-
cific for FPR1 [10,16] but Boc-MLF can antagonise FPR1 and FPR2/ALX at higher concentra-
tions, whilst WRW4 is specific for FPR2/ALX [31].
The FPRa14 agonist’s ability to activate both FPR1 and FPR2/ALX [25] is much more likely
to mimic the actions of naturally occurring endogenous and exogenous FPR agonists that tar-
get multiple receptor isoforms [4].
Our results suggest that both FPR1 and FPR2 are activated in N2a differentiation responses,
whilst FPR2 is involved in the N2a toxicity responses observed. The siRNA experiments sug-
gest that N2a cells endogenously expresses both FPR1 and FPR2 that, when activated via
FPRa14, promotes neuronal differentiation leading to neurite outgrowth and other unique
morphological responses at low micromolar concentrations. Studies in rat neural stem cells
show the activation of FPR1 and FPR2/ALX leads to increased migration and differentiation
[23,24] suggesting that FPR-induced differentiation may be a general feature of neuronal cells.
The involvement of a different pathway in the FPRa14 induced toxicity could play a role in
some of these observed effects on differentiation, as FPRa14 was found to trigger N2a cell dif-
ferentiation at concentrations of 2–10μM (Fig 2), whilst it also elicits slight neurotoxicity at a
concentration of 10μM (Fig 6D). It can be postulated that growth factor expressional changes
[11] could occur within N2a populations at sub-toxic agonist concentrations in order to
increase proliferation and survival. It is important here to consider the implications of the
presence of cell carcasses within the test fields. Whilst it is likely that the majority of cell mate-
rial becomes detached from the culture plate following apoptosis and therefore should not be
present within the photomicrographs used in these assays, there is a distinct possibility that a
small proportion of cell carcasses as well as other cellular debris will remain impacting results.
To negate this possibility the viability of the differentiated forms was determined using trypan
blue dye exclusion and this was shown to be greater than 60% for all differentiated morpholo-
gies when cultures were exposed to the highest agonist concentrations used (10μM).
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This study has demonstrated FPRa14-stimulation of both differentiation and cytotoxicity
in N2a cells–interestingly, there are several possible implications of this phenomenon when
the in vivo situation is considered. FPRs are known to be present in high concentrations within
the olfactory sensory systems such as the vomeronasal organ utilised by many mammals to
identify the presence of odorants and pathogens [9]. Olfactory dysfunction has been
highlighted as an early clinical symptom of AD, and is linked to the neurodegeneration seen in
AD [41]. A key compound in the pathogenesis of AD is amyloid-β, which is also a known ago-
nist of FPR1 and FPR2/ALX [16]. Amyloid-β is also linked to other conditions including Par-
kinson’s disease [42]. FPR activation has demonstrated to increase the production of ROS
[24], abnormally high levels of which have been detected in the brain and bloodstream of AD
patients [43]. It is therefore possible that amyloid-β activates FPRs within nervous tissues, lead-
ing to the generation of ROS and the activation of microglia leading to chronic neuroinflam-
mation and cell death, and thus exacerbating the progression of AD. In the same way, it is
possible that activation of FPR via the prion peptide fragment PrP106-126, another known FPR
agonist [16], may exacerbate the progression of prion disease, in which ROS generation and
microglial activation are known to contribute to disease pathogenesis [44].
Increased FPR1 expression in neuroblastoma primary tumours is correlated with high-
invasiveness and low patient survival rates [10], which may be influenced by the FPR-induced
differentiation reported here. FPR1 is known to play a role in tumourigenicity of other cancers
including glioblastoma [13] and hepatocellular carcinoma [45]. The agonist FPRa14 has been
demonstrated to increase neutrophils and stimulate hepatocarcinogenesis in zebrafish [46].
Our results in combination with these suggest the potential for FPR antagonism as a therapy
for neuroblastoma. Baracco et al. [47] found that specific FPR1 antagonism reduced the effi-
cacy of chemotherapy in a mouse breast cancer model via an immmunosupressive action,
whilst this is not in a neuronal setting it may suggest that the multiple actions of FPR could
play a role in vivo and limit the effectiveness of FPR1 antagonism in cancer chemotherapy. It is
worth noting that FPR1 activation has a cytotoxic effect in our model and therefore FPR1
antagonism could potentially block a beneficial action in a cancer setting.
This study demonstrates the ability of FPR2 activation to cause toxicity whilst combinations
of FPR1 and/or FPR2 activation elicits neuronal differentiation, providing evidence for the idea
that the functionality of this receptor family stretches beyond the immune and inflammatory
responses. The observation of neuronal differentiation mediated via FPR in this study, plus the
demonstration of FPR-mediated neural stem cell differentiation by Wang et al. [23] and Zhang
et al. [24] together represent significant findings and suggest a role for FPR in the CNS. If the
function of FPRs within the CNS could be further characterised, it may bring about promising
advancements in the field of neuronal regeneration, and novel therapies for a range of condi-
tions including strokes, neuropathic pain, neurological cancers and neurodegeneration.
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